Printer Friendly
The Free Library
14,799,752 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Medtronic Combines Vascular and Cardiac Surgery Businesses.


New CardioVascular Business Assembles Full Spectrum of Surgical and Minimally Invasive Products for Cardiovascular Disease Cardiovascular disease
Disease that affects the heart and blood vessels.

Mentioned in: Lipoproteins Test

cardiovascular disease 
 

MINNEAPOLIS -- Medtronic, Inc. (NYSE NYSE

See: New York Stock Exchange
:MDT MDT
abbr.
Mountain Daylight Time


MDT (in the US and Canada) Mountain Daylight Time

MDT n abbr (US) (= mountain daylight time) →
) today announced the formation of Medtronic CardioVascular, a new, global business combining Medtronic's existing Vascular and Cardiac Surgery businesses.

The new CardioVascular business at Medtronic will bring together people, technology and worldwide operations focused on delivering products, treatments and therapies for coronary artery coronary artery
n.
1. An artery with origin in the right aortic sinus; with distribution to the right side of the heart in the coronary sulcus, and with branches to the right atrium and ventricle, including the atrioventricular branches and
, vascular and structural heart disease. The new business will have combined revenues of approximately $1.9 billion (FY07) and will consist of four major divisions:

* Coronary and Peripheral - minimally invasive catheter and stent-based technologies for the treatment of atherosclerosis;

* Endovascular Innovations - stent grafts for the treatment of aortic aortic

pertaining to or emanating from the aorta. See also aortic arch.


aortic aneurysm
occurs most often in dogs, where it is caused by Spirocerca lupi larvae, turkeys and primates, causing dyspnea, cyanosis and coughing.
 abdominal and thoracic aneurysms;

* Structural Heart Disease - products for the treatment of heart valve disease and atrial fibrillation atrial fibrillation

Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection.
; and

* Revascularization and Surgical Therapies - open heart and coronary bypass coronary bypass

Surgical treatment for coronary heart disease to relieve angina pectoris and prevent heart attacks. It became widely used in the 1960s. One or more blood vessels—usually an artery in the chest or a vein from the leg—are transplanted to create
 grafting surgical products

The four core divisions will remain in their current locations but will leverage common business processes and specific functional infrastructure while expanding scientific knowledge and engineering capabilities to advance cardiovascular care.

"Medtronic is combining these two world-class organizations to more strategically align our resources and investments aimed at treating and improving the lives of patients with cardiovascular disease," said William Hawkins, president and chief operating officer Chief Operating Officer (COO)

The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president.
 of Medtronic. "This new business unit also provides Medtronic the opportunity for more growth, as we translate certain efficiencies gained by this combination into new investments in research, clinical studies and technology."

The new CardioVascular business unit will be led by Scott Ward, who currently serves as senior vice president and president of the company's Vascular business. Ward joined Medtronic in 1981 and has been president of the Vascular business since May 2004. Prior to his current position, Ward served as president of the company's Neurological and Diabetes businesses.

"The new CardioVascular business will assemble an exceptional collection of people, technology and global operations that will be focused on collaborating with physicians to improve the quality of care for people with cardiovascular disease," said Ward. "Medtronic will continue to be a powerful innovative force supporting the convergence of cardiovascular specialties focused on applying both surgical and minimally invasive approaches to patient care."

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology, alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K Form 10-K

A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.


Form 10-K

See 10-K.
 for the year ended April 28, 2006. Actual results may differ materially from anticipated results.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 11, 2007
Words:426
Previous Article:Apthera Engages Ferghana Partners for Private Equity Financings.
Next Article:Fitch Rates Illinois' $150MM GOs 'AA'; Outlook Negative.
Topics:



Related Articles
Earnings up at Medtronic. (The Digest).
New technology may bring pain relief to bypass patients.(Silberg TPS system)
Heart health gets a boost from hospital-UO partnership.(Columns)(Column)
Medtronic Reports Second Quarter Revenue Growth of 15% and 23% Growth in Diluted EPS Before Special Items; After Special Items, as Reported Diluted...
Medtronic Octopus(R) Evolution Tissue Stabilizer Offers New Flexibility, Stability to Surgeons Repairing a Beating Heart; Next-Generation Instrument...
Diversified Business Portfolio Helps Medtronic Report Strong First Quarter Earnings Per Share.
Medtronic Announces Initiation of U.S. Feasibility Trial to Evaluate Surgical Ablation Techniques to Treat Lone Atrial Fibrillation.
Medtronic Third Quarter EPS Up 11 Percent on Revenue Growth of 10 Percent.(Financial report)
Medtronic's Cardiovascular Business Receives Product Line Leadership Award for Innovation in Cardiac Surgery.
Medtronic Annual Revenue of $12.3 Billion Generates 15% Growth in Earnings Per Share.

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles